[{"id":"819807a7-627e-40e5-a967-fc5eec1c4f69","acronym":"TARGET","url":"https://clinicaltrials.gov/study/NCT02824133","created_at":"2021-01-18T13:50:52.751Z","updated_at":"2024-07-02T16:36:59.263Z","phase":"Phase 1/2","brief_title":"Treatment With AZD4547 for Recurrent Malignant Glioma Expressing FGFR-TACC Gene Fusion\"","source_id_and_acronym":"NCT02824133 - TARGET","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" FGFR • TACC3 • TACC1","pipe":" | ","alterations":" FGFR fusion • FGFR1 fusion • FGFR3 fusion • FGFR1 expression • TACC3 expression • FGFR3 expression • FGFR1-TACC1 fusion","tags":["FGFR • TACC3 • TACC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR fusion • FGFR1 fusion • FGFR3 fusion • FGFR1 expression • TACC3 expression • FGFR3 expression • FGFR1-TACC1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fexagratinib (ABSK091)"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 09/01/2015","start_date":" 09/01/2015","primary_txt":" Primary completion: 09/01/2017","primary_completion_date":" 09/01/2017","study_txt":" Completion: 10/01/2018","study_completion_date":" 10/01/2018","last_update_posted":"2019-05-29"}]